Will This ETF Beat the Market Over the Next 12 Months?
2024 was another banner year for the US stock market,…
Sell
18
CANC Quote, Financials, Valuation and Earnings
Last price:
$24.65
Seasonality move
:
5.84%
Day range:
$24.35 - $25.31
52-week range:
$24.00 - $30.11
Dividend yield:
2.95%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
14.6K
Avg. volume:
12.1K
1-year change:
-5.97%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CANC
Tema Oncology ETF
|
-- | -- | -- | -- | -- |
|
BMED
iShares Health Innovation Active ETF
|
-- | -- | -- | -- | -- |
|
FMED
Fidelity Disruptive Medicine ETF
|
-- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
-- | -- | -- | -- | -- |
|
MEDI
Harbor Health Care ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CANC
Tema Oncology ETF
|
$24.72 | -- | -- | -- | $0.96 | 2.95% | -- |
|
BMED
iShares Health Innovation Active ETF
|
$25.34 | -- | -- | -- | $0.01 | 0% | -- |
|
FMED
Fidelity Disruptive Medicine ETF
|
$25.20 | -- | -- | -- | $0.11 | 0.45% | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
$9.97 | -- | -- | -- | $0.00 | 0% | -- |
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
$29.39 | -- | -- | -- | $0.47 | 0.49% | -- |
|
MEDI
Harbor Health Care ETF
|
$25.46 | -- | -- | -- | $0.13 | 0.53% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CANC
Tema Oncology ETF
|
-- | 1.218 | -- | -- |
|
BMED
iShares Health Innovation Active ETF
|
-- | 1.140 | -- | -- |
|
FMED
Fidelity Disruptive Medicine ETF
|
-- | 1.072 | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | 2.174 | -- | -- |
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
-- | 1.482 | -- | -- |
|
MEDI
Harbor Health Care ETF
|
-- | 1.375 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CANC
Tema Oncology ETF
|
-- | -- | -- | -- | -- | -- |
|
BMED
iShares Health Innovation Active ETF
|
-- | -- | -- | -- | -- | -- |
|
FMED
Fidelity Disruptive Medicine ETF
|
-- | -- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
-- | -- | -- | -- | -- | -- |
|
MEDI
Harbor Health Care ETF
|
-- | -- | -- | -- | -- | -- |
Tema Oncology ETF vs. Competitors
-
Which has Higher Returns CANC or BMED?
iShares Health Innovation Active ETF has a net margin of -- compared to Tema Oncology ETF's net margin of --. Tema Oncology ETF's return on equity of -- beat iShares Health Innovation Active ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CANCTema Oncology ETF-- -- -- BMEDiShares Health Innovation Active ETF-- -- -- -
What do Analysts Say About CANC or BMED?
Tema Oncology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Health Innovation Active ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema Oncology ETF has higher upside potential than iShares Health Innovation Active ETF, analysts believe Tema Oncology ETF is more attractive than iShares Health Innovation Active ETF.
Company Buy Ratings Hold Ratings Sell Ratings CANCTema Oncology ETF0 0 0 BMEDiShares Health Innovation Active ETF0 0 0 -
Is CANC or BMED More Risky?
Tema Oncology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iShares Health Innovation Active ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CANC or BMED?
Tema Oncology ETF has a quarterly dividend of $0.96 per share corresponding to a yield of 2.95%. iShares Health Innovation Active ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.01 per share. Tema Oncology ETF pays -- of its earnings as a dividend. iShares Health Innovation Active ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANC or BMED?
Tema Oncology ETF quarterly revenues are --, which are smaller than iShares Health Innovation Active ETF quarterly revenues of --. Tema Oncology ETF's net income of -- is lower than iShares Health Innovation Active ETF's net income of --. Notably, Tema Oncology ETF's price-to-earnings ratio is -- while iShares Health Innovation Active ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema Oncology ETF is -- versus -- for iShares Health Innovation Active ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANCTema Oncology ETF-- -- -- -- BMEDiShares Health Innovation Active ETF-- -- -- --
-
Which has Higher Returns CANC or FMED?
Fidelity Disruptive Medicine ETF has a net margin of -- compared to Tema Oncology ETF's net margin of --. Tema Oncology ETF's return on equity of -- beat Fidelity Disruptive Medicine ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CANCTema Oncology ETF-- -- -- FMEDFidelity Disruptive Medicine ETF-- -- -- -
What do Analysts Say About CANC or FMED?
Tema Oncology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Fidelity Disruptive Medicine ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema Oncology ETF has higher upside potential than Fidelity Disruptive Medicine ETF, analysts believe Tema Oncology ETF is more attractive than Fidelity Disruptive Medicine ETF.
Company Buy Ratings Hold Ratings Sell Ratings CANCTema Oncology ETF0 0 0 FMEDFidelity Disruptive Medicine ETF0 0 0 -
Is CANC or FMED More Risky?
Tema Oncology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fidelity Disruptive Medicine ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CANC or FMED?
Tema Oncology ETF has a quarterly dividend of $0.96 per share corresponding to a yield of 2.95%. Fidelity Disruptive Medicine ETF offers a yield of 0.45% to investors and pays a quarterly dividend of $0.11 per share. Tema Oncology ETF pays -- of its earnings as a dividend. Fidelity Disruptive Medicine ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANC or FMED?
Tema Oncology ETF quarterly revenues are --, which are smaller than Fidelity Disruptive Medicine ETF quarterly revenues of --. Tema Oncology ETF's net income of -- is lower than Fidelity Disruptive Medicine ETF's net income of --. Notably, Tema Oncology ETF's price-to-earnings ratio is -- while Fidelity Disruptive Medicine ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema Oncology ETF is -- versus -- for Fidelity Disruptive Medicine ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANCTema Oncology ETF-- -- -- -- FMEDFidelity Disruptive Medicine ETF-- -- -- --
-
Which has Higher Returns CANC or GNOM?
Global X Genomics & Biotechnology ETF has a net margin of -- compared to Tema Oncology ETF's net margin of --. Tema Oncology ETF's return on equity of -- beat Global X Genomics & Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CANCTema Oncology ETF-- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -
What do Analysts Say About CANC or GNOM?
Tema Oncology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Genomics & Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema Oncology ETF has higher upside potential than Global X Genomics & Biotechnology ETF, analysts believe Tema Oncology ETF is more attractive than Global X Genomics & Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings CANCTema Oncology ETF0 0 0 GNOMGlobal X Genomics & Biotechnology ETF0 0 0 -
Is CANC or GNOM More Risky?
Tema Oncology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Global X Genomics & Biotechnology ETF has a beta of 1.142, suggesting its more volatile than the S&P 500 by 14.178%.
-
Which is a Better Dividend Stock CANC or GNOM?
Tema Oncology ETF has a quarterly dividend of $0.96 per share corresponding to a yield of 2.95%. Global X Genomics & Biotechnology ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tema Oncology ETF pays -- of its earnings as a dividend. Global X Genomics & Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANC or GNOM?
Tema Oncology ETF quarterly revenues are --, which are smaller than Global X Genomics & Biotechnology ETF quarterly revenues of --. Tema Oncology ETF's net income of -- is lower than Global X Genomics & Biotechnology ETF's net income of --. Notably, Tema Oncology ETF's price-to-earnings ratio is -- while Global X Genomics & Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema Oncology ETF is -- versus -- for Global X Genomics & Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANCTema Oncology ETF-- -- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- --
-
Which has Higher Returns CANC or HRTS?
Tema GLP-1, Obesity & Cardiometabolic ETF has a net margin of -- compared to Tema Oncology ETF's net margin of --. Tema Oncology ETF's return on equity of -- beat Tema GLP-1, Obesity & Cardiometabolic ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CANCTema Oncology ETF-- -- -- HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- -
What do Analysts Say About CANC or HRTS?
Tema Oncology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Tema GLP-1, Obesity & Cardiometabolic ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema Oncology ETF has higher upside potential than Tema GLP-1, Obesity & Cardiometabolic ETF, analysts believe Tema Oncology ETF is more attractive than Tema GLP-1, Obesity & Cardiometabolic ETF.
Company Buy Ratings Hold Ratings Sell Ratings CANCTema Oncology ETF0 0 0 HRTSTema GLP-1, Obesity & Cardiometabolic ETF0 0 0 -
Is CANC or HRTS More Risky?
Tema Oncology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tema GLP-1, Obesity & Cardiometabolic ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CANC or HRTS?
Tema Oncology ETF has a quarterly dividend of $0.96 per share corresponding to a yield of 2.95%. Tema GLP-1, Obesity & Cardiometabolic ETF offers a yield of 0.49% to investors and pays a quarterly dividend of $0.47 per share. Tema Oncology ETF pays -- of its earnings as a dividend. Tema GLP-1, Obesity & Cardiometabolic ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANC or HRTS?
Tema Oncology ETF quarterly revenues are --, which are smaller than Tema GLP-1, Obesity & Cardiometabolic ETF quarterly revenues of --. Tema Oncology ETF's net income of -- is lower than Tema GLP-1, Obesity & Cardiometabolic ETF's net income of --. Notably, Tema Oncology ETF's price-to-earnings ratio is -- while Tema GLP-1, Obesity & Cardiometabolic ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema Oncology ETF is -- versus -- for Tema GLP-1, Obesity & Cardiometabolic ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANCTema Oncology ETF-- -- -- -- HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- --
-
Which has Higher Returns CANC or MEDI?
Harbor Health Care ETF has a net margin of -- compared to Tema Oncology ETF's net margin of --. Tema Oncology ETF's return on equity of -- beat Harbor Health Care ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CANCTema Oncology ETF-- -- -- MEDIHarbor Health Care ETF-- -- -- -
What do Analysts Say About CANC or MEDI?
Tema Oncology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Harbor Health Care ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema Oncology ETF has higher upside potential than Harbor Health Care ETF, analysts believe Tema Oncology ETF is more attractive than Harbor Health Care ETF.
Company Buy Ratings Hold Ratings Sell Ratings CANCTema Oncology ETF0 0 0 MEDIHarbor Health Care ETF0 0 0 -
Is CANC or MEDI More Risky?
Tema Oncology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Harbor Health Care ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CANC or MEDI?
Tema Oncology ETF has a quarterly dividend of $0.96 per share corresponding to a yield of 2.95%. Harbor Health Care ETF offers a yield of 0.53% to investors and pays a quarterly dividend of $0.13 per share. Tema Oncology ETF pays -- of its earnings as a dividend. Harbor Health Care ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANC or MEDI?
Tema Oncology ETF quarterly revenues are --, which are smaller than Harbor Health Care ETF quarterly revenues of --. Tema Oncology ETF's net income of -- is lower than Harbor Health Care ETF's net income of --. Notably, Tema Oncology ETF's price-to-earnings ratio is -- while Harbor Health Care ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema Oncology ETF is -- versus -- for Harbor Health Care ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANCTema Oncology ETF-- -- -- -- MEDIHarbor Health Care ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Carlos Slim Buy PBF Energy?
Carlos Slim made a splash in a surprising sector last…
Is Booking Holdings Stock Undervalued?
There is a lot of humdrum in the market about…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 121x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Sell
39
DOGZ alert for Jan 4
Dogness (International) [DOGZ] is down 20.52% over the past day.
Buy
66
DMRC alert for Jan 4
Digimarc [DMRC] is up 16.19% over the past day.
Sell
39
MSTR alert for Jan 4
MicroStrategy [MSTR] is up 13.33% over the past day.
